BenchSci

BenchSci in its US$22 million Series B round

Client

BenchSci

Value

US$22 million

Service

Emerging and High Growth Companies

Date Closed

February 2020

Industry

Venture Capital

Lead Office

Toronto


 

On February 4, 2020, BenchSci completed its US$22 million Series B financing round led by F-Prime Capital. The funding will be used to launch new offerings including an AI-assisted reagent selection product, and an expansion of its contract with Novartis.

BenchSci is a technology firm specialized in healthcare technology focused on using biomedical artificial intelligence to help researchers run successful experiments.

F-Prime Capital is an investment firm specialized in investments in healthcare and technology focused growth stage companies.

Osler, Hoskin & Harcourt LLP advised BenchSci with a team consisting of Chad Bayne, Justin Dharamdial and Shalu Atwal (Emerging and High Growth Companies).


Team
Chad Bayne
Key Contact

Chad Bayne

Partner, Emerging and High Growth Companies

Justin Dharamdial

Justin Dharamdial

Associate, Emerging and High Growth Companies

Shalu is an associate in the firm’s Emerging and High Growth Companies Group.

Shalu Atwal

Associate, Emerging and High Growth Companies